3M Company vs Summit Therapeutics Inc — how do they compare? 3M Company trades at $170.8 (market cap $82.99B), while Summit Therapeutics Inc trades at $14.57 (market cap $10.48B). The key difference: 3M Company is far larger — about 7.9× Summit Therapeutics Inc's market cap, and 3M Company pays a 1.96% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MMM | SMMT | |
|---|---|---|
Market Cap | $82.99B | $10.48B |
Sector | Industrials | Health |
52-Week High | $174.61 | $29.32 |
52-Week Low | $141.10 | $13.05 |
Enterprise Value | $91.39B | $9.90B |
Dividend Yield | 1.96% | — |
Signals from Pluang's Aura AI — not financial advice
3M (MMM) surged 6.83% to $170.76 following strong Q2 2026 earnings that beat expectations, with the company raising full-year guidance. Technical indicators show a bullish trend with support at $158 and resistance at $161. Fundamentally, the company demonstrates robust profitability with 39.71% gross margins and 72.14% ROE, though revenue has declined from 2022 peaks. Recent news highlights operational improvements and growth in Safety & Industrial and Transport & Electronics segments.
The outlook is positive with earnings momentum and raised guidance, but risks include litigation liabilities and macroeconomic headwinds. Analyst consensus is mixed with 48% buy ratings but a $149.75 price target below current levels, suggesting limited near-term upside despite strong operational performance.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →